statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half...

Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results

Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for...

Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Kronos Bio (KRON Research Report), with a price target...

Piper Sandler Remains a Buy on Kronos Bio (KRON)

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today...

Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced...

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

Company eliminates three executive officer roles and appoints new Executive Leadership teamSAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq...

Kronos Bio Implements New Leadership Structure to Drive Pipeline Advancement

Kronos Bio, Inc. (NASDAQ:KRON  Get Free Report) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totalling 2,430,000 shares, a...

Short Interest in Kronos Bio, Inc. (NASDAQ:KRON) Declines By 10.7%

Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.

Watchers	766
52-Wk Low	$0.731
52-Wk High	$2.29

Volume	255,282.00
52-Wk High	$2.29
52-Wk Low	$0.731

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.36	--	--	N/A
Q1'24	-$0.42	-$0.50	-18.34%	MISSED
Q4'23	-$0.54	-$0.43	19.88%	BEAT
Q3'23	-$0.51	-$0.54	-5.37%	MISSED
Q2'23	-$0.46	-$0.52	-13.04%	MISSED

KRON Kronos Bio Inc

About

Feed

News

Sentiment

Earnings

Fundamentals